Pharmaceutical

RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia

RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia

articleRibomic, Inc.July 1, 20264/news/ribomic-announces-first-patient-in-fpi-in-the-phase-3-clinical-trial-of-umedaptanib-pegol-in-the-treatment-of-achondroplasia
RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia

About this update from Ribomic, Inc.

Ribomic, Inc. (4591) Press ReleaseView Attachment

View stock analysis, news, and events for Ribomic, Inc.